Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) Receives Average Recommendation of “Buy” from Analysts

Shares of Corvus Pharmaceuticals, Inc. (NASDAQ:CRVS) have been given a consensus recommendation of “Buy” by the four analysts that are covering the stock, MarketBeat.com reports. Three analysts have rated the stock with a buy recommendation and one has given a strong buy recommendation to the company. The average twelve-month price target among brokers that have covered the stock in the last year is $12.83.

A number of analysts have recently issued reports on CRVS shares. Mizuho upgraded Corvus Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a report on Tuesday, October 22nd. StockNews.com downgraded Corvus Pharmaceuticals from a “hold” rating to a “sell” rating in a research note on Thursday, October 31st. LADENBURG THALM/SH SH lifted their price objective on shares of Corvus Pharmaceuticals from $12.00 to $21.00 and gave the company a “buy” rating in a research note on Monday, September 16th. Oppenheimer boosted their target price on Corvus Pharmaceuticals from $8.00 to $14.00 and gave the stock an “outperform” rating in a report on Wednesday, November 13th. Finally, HC Wainwright assumed coverage on shares of Corvus Pharmaceuticals in a research report on Thursday. They set a “buy” rating and a $11.00 target price for the company.

Institutional Trading of Corvus Pharmaceuticals

Several institutional investors have recently bought and sold shares of CRVS. Samlyn Capital LLC lifted its holdings in Corvus Pharmaceuticals by 160.7% during the 2nd quarter. Samlyn Capital LLC now owns 6,123,021 shares of the company’s stock valued at $11,144,000 after purchasing an additional 3,774,658 shares during the last quarter. Marshall Wace LLP bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $136,000. Cubist Systematic Strategies LLC bought a new position in shares of Corvus Pharmaceuticals in the second quarter valued at approximately $44,000. Point72 Asset Management L.P. acquired a new position in shares of Corvus Pharmaceuticals in the 2nd quarter worth approximately $10,855,000. Finally, Avity Investment Management Inc. grew its position in Corvus Pharmaceuticals by 138.2% during the 3rd quarter. Avity Investment Management Inc. now owns 27,580 shares of the company’s stock worth $146,000 after acquiring an additional 16,000 shares during the last quarter. Institutional investors and hedge funds own 46.64% of the company’s stock.

Corvus Pharmaceuticals Stock Performance

Corvus Pharmaceuticals stock opened at $5.35 on Thursday. Corvus Pharmaceuticals has a 1 year low of $1.30 and a 1 year high of $10.00. The firm’s 50 day moving average price is $7.77 and its two-hundred day moving average price is $5.26. The firm has a market cap of $343.77 million, a price-to-earnings ratio of -5.75 and a beta of 1.05.

About Corvus Pharmaceuticals

Corvus Pharmaceuticals, Inc, a clinical stage biopharmaceutical company, focuses on the development and commercialization of immune modulator product candidates to treat solid cancers, T cell lymphomas, autoimmune, allergic, and infectious diseases. Its lead product candidate is soquelitinib (CPI-818), a selective covalent inhibitor of interleukin 2 inducible T cell kinase (ITK), which is in a multi-center Phase 1/1b clinical trial for the treatment of peripheral T cell lymphoma, solid tumors, and atopic dermatitis.